Source link : https://www.newshealth.biz/health-news/fda-approves-donanemab-for-early-alzheimers/
The US Food and Drug Administration (FDA) has approved Eli Lilly’s anti-amyloid donanemab (Kisunla) 350 mg/20 mL once-monthly injection for intravenous infusion for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease with confirmed amyloid pathology. Once-monthly donanemab is “the first and only amyloid plaque-targeting […]
Author : News Health
Publish date : 2024-07-02 19:54:35
Copyright for syndicated content belongs to the linked Source.
inHealth